Karyopharm Therapeutics Inc. filed Chapter 11 on November 2, 2026, cannot file its Form 10-Q, and Nasdaq suspended trading on November 11, 2026. Its plan cancels equity without distribution, with Ayrmid transaction expected to close in first quarter of 2027.
KPTI · Karyopharm Therapeutics Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
After Karyopharm Therapeutics Inc. filed Chapter 11 petitions on November 2, 2026, Nasdaq notified it that securities will be delisted. Trading will suspend November 11, 2026; it will not appeal and expects existing equity securities to have no value.
Karyopharm Therapeutics Inc. and KPT Texas LLC filed Chapter 11 on November 2, 2026, seeking a $110 million DIP facility and an Ayrmid-led restructuring that would cancel existing equity.
Karyopharm Therapeutics Inc. plans a merger with Ayrmid Ltd. and filed Chapter 11 petitions. The deal is expected to close in the first quarter of 2027 with up to $55 million in DIP financing; equity is expected to have no value.
Karyopharm Therapeutics Inc. further extended the end of its forbearance period from 11:59 p.m., Eastern time, on October 22, 2026 to 11:59 p.m., Eastern time, on November 1, 2026, absent earlier termination.
On October 13, 2026, Karyopharm Therapeutics Inc. extended the date the Forbearance Period will end, absent earlier termination, from 11:59 p.m., Eastern time, on October 15, 2026 to 11:59 p.m., Eastern time, on October 22, 2026.